Big pharma's patent cliff meets a new biotech Cold War: We need to outrun China, not outlaw it If we slash federal research budgets, we risk hamstringing our scientists and losing an otherwise winnable race. Fortune · Jul 24
Former GlaxoSmithKline HQ in west London to be transformed into 1,500 new homes Ambitious plans to redevelop the former headquarters of GlaxoSmithKline in Brentford have been given the green light Evening Standard · Mar 9
23andMe is potentially selling more than just genetic data – the personal survey info it collected is just as much a privacy problem As soon as the genetic testing company 23andMe filed for bankruptcy on March 23, 2025, concerns about what would happen to the personal information contained in its massive genetic and health information database were swift and widespread. A few days after, a U.S. judge ruled that the company could sell… The Conversation · Apr 2, 2025
Treatment for Parkinson’s disease and restless leg syndrome is linked with risky behaviour – here’s what you need to know Getting a headache and feeling sick are common side-effects for many medicines. Indulging in risky sexual behaviour or pathological gambling – not so common. The Conversation · Mar 14, 2025
Pharma company funding for patient advocacy groups needs to be transparent Patient groups should be playing a central role in Canada’s health-care system, advocating for their members by promoting the visibility of their conditions, pushing for more rapid and accurate diagnoses and lobbying for the introduction and funding of new treatments and drugs that may help relieve their members’ symptoms and… The Conversation · Oct 2, 2024
RSV is linked to asthma in children – but we can’t say one causes the other yet As winter rolls on in Australia, respiratory viruses are everywhere. One of the main culprits is respiratory syncytial virus, or RSV, which has caused more than 145,000 infections around the country so far this year. Most are in children under five. The Conversation · Aug 27, 2024
GSK’s health is improving. Shame about the legal heartburn Emma Walmsley’s overhaul seems to be delivering the goods even if US worries have left the share price becalmed The Guardian - UK · Jul 31, 2024
Experts say Medicaid rebate change is behind inhaler price cuts - Roll Call Three inhaler manufacturers will cap patient copays for their inhalers at $35 a month and lower the list prices of some of those products. Roll Call · Mar 26, 2024
Flovent Asthma Medication Discontinued In U.S., Impacting Families The discontinuation of childhood asthma medication Flovent in the U.S. has led to challenges with the transition to the generic version, impacting parents,... Top News · Feb 20, 2024
GSK Slashes US Prices for Advair, Valtrex, Lamictal GSK, the pharmaceutical giant, is taking a bold step by announcing price reductions for popular drugs Advair, Valtrex, and Lamictal in the US. A refreshing... Top News · Dec 23, 2023
Pharma giant tops new business gender equality index ‘Lead5050 Index provides a comprehensive snapshot of how well employers tackle the gender pay gap’ The Independent UK · Feb 6, 2023
GlaxoSmithKline tops new business gender equality index The Equity Index 2022/23 produced by Lead 5050 ranked firms using official data on average salaries, bonuses, and pay. The Independent UK · Feb 6, 2023
Lisa Jarvis: What parents can do as RSV spikes among children A surge in cases of a common respiratory virus is filling up pediatric hospital beds around the U.S. The early and swift arrival of respiratory syncytial virus, or RSV, is stretching the limits of an already exhausted health care system. Layer on COVID and the flu, and you’ve got the… Tribune News Service · Oct 27, 2022
Chemical engineer fired by pharma giant GlaxoSmithKline after racist, homophobic rant on plane Man mentioned employer GlaxoSmithKline in rant, calling it ‘one of the best f***ing companies in the world’ The Independent UK · Sep 5, 2022
Benzinga · May 16, 2022 GlaxoSmithKline: Dividend Insights Wednesday marks the last chance for investors to receive the next dividend payout from GlaxoSmithKline (NYSE:GSK).
The Guardian - UK · May 10, 2022 Boots, Superdrug and other chemists report hay fever pill shortages GlaxoSmithKline blames shortage of key ingredient for lack of Piriton and Piriteze tablets
StockNews.com · May 6, 2022 3 High-Yield Dividend Stocks to Buy in May: GlaxoSmithKline, A.P. Moeller-Maersk, and ENI With the latest federal interest rate hike and the possibility of further monetary policy tightening, market indices have been going haywire. Because volatility is expected to persist, with experts fearing the economy will slip into recession, we think it could be wise to bet on high dividend-yielding stocks GlaxoSmithKline (GSK),…
The Guardian - UK · May 4, 2022 Radical plans to transform NHS drawn up at drug firms and No 10 roundtable Exclusive: ideas include reducing trial safeguards and allowing startups to harvest patient data
Benzinga · Apr 27, 2022 Recap: GlaxoSmithKline Q1 Earnings GlaxoSmithKline (NYSE:GSK) reported its Q1 earnings results on Wednesday, April 27, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Benzinga · Apr 26, 2022 GlaxoSmithKline's Earnings Outlook GlaxoSmithKline (NYSE:GSK) is set to give its latest quarterly earnings report on Wednesday, 2022-04-27. Here's what investors need to know before the announcement. Analysts estimate that GlaxoSmithKline will report an earnings per share (EPS) of $0.76.
Evening Standard · Apr 19, 2022 GlaxoSmithKline and AstraZeneca secure victories with US drug regulator GlaxoSmithKline’s drug aimed at chronic kidney disease patients with anaemia and AstraZeneca’s lung cancer treatment have both moved a step closer to getting the green light
The Guardian - UK · Mar 17, 2022 GlaxoSmithKline says it will not start any new clinical trials in Russia Pharma firm joins AstraZeneca and Pfizer in saying it will not enrol new patients into studies
Benzinga · Feb 25, 2022 Does CBD Have To Be Water Soluble? One Group Of Scientists Say Yes For Better Absorption Several former scientists and staff from companies like Johnson & Johnson (NYSE: JNJ), GlaxoSmithKline (NYSE: GSK) and Schiff Nutrition are bringing a new delivery platform to market that boosts the bioavailability of&
Radio France Internationale · Feb 24, 2022 France's Sanofi to seek Covid vaccine approval after months of delays French pharmaceuticals giant Sanofi has said that its Covid-19 vaccine, developed with Britain's GlaxoSmithKline, had delivered positive results after nearly a year of setbacks that left it lagging far behind its rivals.
The Independent UK · Feb 23, 2022 New Covid vaccine 100% effective against severe disease, manufacturers say French pharmaceutical Sanofi and its British partner GlaxoSmithKline hope their vaccine will also be used as a booster